NASDAQ
05.12.25 | 22:00
1,390 US-Dollar
-0,71 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11. | Zentalis Pharmaceuticals GAAP EPS of -$0.37 | 2 | Seeking Alpha | ||
| 10.11. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.10. | Zentalis to present azenosertib data at cancer therapeutics conference | 5 | Investing.com | ||
| 01.10. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 73 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.09. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 126 | GlobeNewswire (Europe) | SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.08. | Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary | 4 | GlobeNewswire (USA) | ||
| 26.08. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 147 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 18.06. | Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung | 3 | Investing.com Deutsch | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 106 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 171 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 172 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 26.03. | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 190 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
| 03.03. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 158 | GlobeNewswire (Europe) | SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 03.02. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 174 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule... ► Artikel lesen | |
| 29.01. | Pre-market Movers: Silexion Therapeutics, Zentalis Pharmaceuticals, 60 Degrees Pharmaceuticals, Manhattan Associates, Nextracker | 657 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Silexion Therapeutics Corp (SLXN) is up over 65%... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,382 | -0,54 % | Biontech Aktie: CureVac-Fusion vor entscheidender Abstimmung - lohnt sich jetzt das Aktien kaufen? | ||
| MODERNA | 23,785 | 0,00 % | ROUNDUP/Aktien New York: Schwacher Dezember-Auftakt - Augen auf Bitcoin | NEW YORK (dpa-AFX) - Der Start in den Dezember ist am Montag an den US-Börsen schwach ausgefallen. Nach der jüngsten Erholungsrally gingen Anleger in einem Umfeld global wieder sinkender Risikobereitschaft... ► Artikel lesen | |
| VALNEVA | 3,878 | +0,26 % | Valneva: Beim Kursziel der Aktie geht es nach oben | Im ersten Halbjahr 2026 soll es die Ergebnisse einer Phase-3-Studie von Valneva zu einem Impfstoff (VLA 15) gegen Lyme-Borreliose geben. In der Folge könnte bei positiven Ergebnissen die Zulassung in... ► Artikel lesen | |
| NOVAVAX | 5,875 | -0,93 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,437 | +0,46 % | Moderna, Lonza, NurExone: Wie Biotech-Akteure den Weg in neue Wachstumsfelder ebnen | ||
| IMMUNITYBIO | 1,924 | -1,99 % | ImmunityBio (IBRX) Slashes 9% on Lack of Leads | ||
| CARDIFF ONCOLOGY | 1,864 | +2,53 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| ALDEYRA | 4,081 | +0,99 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,889 | +0,20 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| GUARDANT HEALTH | 86,36 | -1,44 % | Guardant Health, Inc.: Guardant Health to Participate in Upcoming Investor Conferences | Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Jefferies Global Healthcare... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,027 | -0,82 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,620 | -1,67 % | Ocular Therapeutix plant Zulassungsantrag für AXPAXLI auf Basis von Phase-3-Daten | ||
| ESPERION | 3,129 | -2,19 % | Esperion Therapeutics, Inc.: Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia | - Company to Receive $90 Million Total Payment - - Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL - ANN ARBOR, Mich., Nov.... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,746 | +1,79 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen |
Das Unternehmen ZENTALIS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,390 Euro und damit -0,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.